Clemastine (Meclastin)

Overview

Clemastine (Dayhist®) is a first-generation H1 antihistamine used in veterinary medicine for the management of allergic conditions in dogs and cats. Like other antihistamines in this class, it reduces the clinical effects of histamine released during allergic reactions.

Compared with many other first-generation antihistamines, clemastine has relatively stronger anticholinergic activity but tends to cause fewer sedative effects. However, its clinical usefulness in dogs may be limited because oral administration results in very low bioavailability and may not consistently achieve therapeutic blood concentrations.

Mechanism of Action (MOA): Clemastine competitively blocks histamine at H1 receptors on target cells. By preventing histamine from binding to these receptors, the drug helps reduce allergic symptoms such as itching, redness, swelling, and increased vascular permeability. Clemastine does not prevent histamine release but instead antagonizes its effects at the receptor level.

Indications

Clemastine is used in dogs and cats primarily as an antihistamine for the management of allergic conditions. By blocking histamine effects at H1 receptors, it can help reduce the clinical signs associated with allergic reactions.

• Allergic skin disease: Used as part of the management of pruritus and inflammation associated with allergic dermatitis in dogs and cats.
• Environmental or seasonal allergies: May help control clinical signs such as itching, redness, and irritation associated with environmental allergens.
• Adjunct therapy in allergic reactions: Can be used alongside other treatments in patients experiencing allergic responses where histamine release contributes to clinical signs.

Clinical response to antihistamines varies between individual animals. In dogs, oral administration may produce limited therapeutic effects because systemic drug levels achieved after oral dosing are often low.

Dosage (Reference)

Dog

Clemastine is used orally in dogs for the management of allergic conditions. However, oral absorption in dogs is very poor, and therapeutic blood levels are not always achieved. Because of this, the clinical response may vary between patients.

Cat

Clemastine may be used orally in cats for allergic conditions. However, pharmacokinetic studies specifically defining optimal dosing in cats are limited.

Warnings & Precautions

Clemastine is generally well tolerated in dogs and cats when used at recommended doses, but its anticholinergic activity and systemic effects require careful patient selection. Certain underlying medical conditions may increase the risk of adverse reactions.

• Hypersensitivity: Clemastine is contraindicated in animals with a known hypersensitivity to the drug or to other antihistamines of the same class.
• Anticholinergic effects: Because clemastine has notable anticholinergic activity, it should be used cautiously in patients with prostatic hypertrophy, bladder neck obstruction, or urinary retention.
• Gastrointestinal obstruction: Use cautiously in animals with pyloroduodenal obstruction or other conditions where decreased gastrointestinal motility could worsen the clinical condition.
• Glaucoma: Anticholinergic effects may increase intraocular pressure; therefore, caution is advised in patients with angle-closure glaucoma.
• Cardiac disease: Use cautiously in animals with severe cardiac failure, as anticholinergic effects may contribute to cardiovascular instability.
• Pregnancy: Although studies in laboratory animals have not demonstrated fetal harm at very high doses, safety in veterinary species has not been fully established. Use during pregnancy only when the expected benefit outweighs potential risks.
• Lactation: Clemastine is excreted into milk and may cause adverse effects in nursing offspring; use cautiously in lactating animals, particularly when nursing neonates.

Drug Interactions

Clemastine may interact with several medications due to its anticholinergic and central nervous system (CNS) depressant properties. Care should be taken when it is used together with drugs that have similar pharmacologic effects.

• Anticholinergic drugs (e.g., atropine, glycopyrrolate): Concurrent use may increase anticholinergic effects such as dry mucous membranes, constipation, decreased tear production, or urinary retention.
• CNS depressants (e.g., anesthetics, benzodiazepines, opioids): Additive central nervous system depression may occur, potentially leading to increased sedation or decreased alertness.
• Monoamine oxidase inhibitors – MAOIs (e.g., selegiline, amitraz, furazolidone, linezolid): These drugs may enhance the anticholinergic effects of clemastine and increase the risk of adverse reactions.

Side Effects & Overdose

Side Effects

Clemastine is generally well tolerated in dogs and cats, but adverse effects can occur due to its antihistamine and anticholinergic properties. Most reactions are mild and resolve after discontinuation of the drug.

• Sedation: Drowsiness may occur in some dogs, although clemastine tends to cause less sedation than many other first-generation antihistamines.
• Paradoxical excitement: Some animals may develop increased activity or agitation instead of sedation.
• Anticholinergic effects: Dryness of mucous membranes, decreased salivation, and reduced tear production may occur.
• Urinary effects: Urinary incontinence, difficulty urinating (dysuria), or straining to urinate (stranguria) have been reported rarely in dogs.
• Depression: Marked lethargy or depression has been reported in rare cases and may require discontinuation of the drug.
• Gastrointestinal effects in cats: Diarrhea is the most commonly reported adverse effect.
• Skin reactions: Rarely, a fixed drug eruption has been reported in a cat receiving clemastine.

Overdose

There is no specific antidote for clemastine overdose. Toxic effects generally represent an exaggerated form of the drug’s pharmacologic actions and require supportive treatment.

• CNS depression or stimulation: Overdose may cause severe sedation, depression, or in some cases central nervous system stimulation.
• Severe anticholinergic effects: Signs may include marked dryness of mucous membranes, tachycardia, urinary retention, and hyperthermia.
• Hypotension: Cardiovascular depression and low blood pressure may occur in severe cases.
• Management: Treatment is mainly supportive. Gastrointestinal decontamination may be considered in recent oral overdoses when appropriate.
• Anticholinergic toxicity treatment: Physostigmine may be used in severe cases involving significant anticholinergic CNS effects.
• Seizure control: Diazepam may be administered if seizures develop.

Key Notes

Practical clinical points that can help optimize the effective use of clemastine in veterinary patients:

• Variable clinical response: As with many antihistamines, the response to clemastine can vary considerably between individual animals; some patients may show good improvement while others may have minimal benefit.
• Best use in allergic disease management: Clemastine is typically used as part of a broader allergy management plan rather than as a sole treatment for severe allergic conditions.
• Timing of therapy: Antihistamines are often more effective when administered before exposure to known allergens or early in the course of allergic flare-ups.
• Monitoring treatment response: Clinical improvement, particularly reduction in pruritus or allergic signs, should be used to guide continuation or adjustment of therapy.
• Product selection: When using over-the-counter formulations, ensure that the product contains clemastine alone and does not include additional active ingredients that may be harmful to animals.